A study conducted by the Mayo Clinic and published in medical journal, Gastroenterology, concluded that Xarelto caused more gastrointestinal (GI) bleeding than two other medications examined, Eliquis and Pradaxa. However, the Mayo Clinic found that all three drugs caused gastrointestinal bleeding. According to Injury Lawyer News, the study included 57,000 patients who were prescribed Eliquis, Pradaxa, and Xarelto from October 1, 2010, to February 28, 2015.
Xarelto, Eliquis, and Pradaxa are blood thinners that contain direct oral anticoagulant (DOAC) agents. Bleeding problems associated with DOAC agents, such as warfarin, can be reversed with vitamin K and fresh frozen plasma. However, if GI bleeding is caused by Xarelto and Eliquis, the bleeding cannot be cured and results can be fatal.
As of now, according to Injury Lawyer News, there are 15,000 lawsuits involving Xarelto. A majority of the suits claim the manufacturers, Bayer Healthcare and Janssen Pharmaceuticals, did not inform their patients that GI bleeding caused by their products were irreversible. They have been charged with selling unreasonably dangerous and defective products.
Product liability suits claim this medication should have never been released before a reversal agent was created.
In the beginning of 2017, Federal district courts will begin having trials involving Xarelto. Settlements are expected to be large because of the increasing number of patients who have experienced bleeding and because of the large market share.